争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2021
Neurocrine 就 Ingrezza 专利起诉 Lupin
提起诉讼
Neurocrine Biosciences 起诉 Lupin，指控其侵犯保护 Ingrezza 的三项专利。Lupin 在其 ANDA 中否认相关专利会被侵犯；Neurocrine 寻求侵权判决及禁令。
来源摘录
Lupin detailed within their ANDA their belief that the patents-in-suit are “invalid, unenforceable or will not be infringed by the manufacture, use or sale of Lupin’s generic products.”
filed suit last Friday against defendants Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc., and Lupin Atlantis Holdings S.A. (collectively, Lupin) in the District of Delaware.
The suit came about due to Lupin’s alleged infringement of three patents held by Neurocrine, all of which protect the drug Ingrezza.